A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease

International Journal of Antimicrobial Agents - Tập 36 - Trang 79-83 - 2010
Bianca P. Olivieri1, Judith Tibisay Molina1, Solange L. de Castro2, Mirian Claudia Pereira3, Claudia M. Calvet3, Julio A. Urbina4, Tania C. Araújo-Jorge1
1Laboratory for Innovations in Therapy, Education and Bioproducts, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil
2Laboratory of Cell Biology, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil
3Laboratory of Cell Ultrastructure, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil
4Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela

Tài liệu tham khảo

Schofield, 2006, The future of Chagas disease control, Trends Parasitol, 22, 583, 10.1016/j.pt.2006.09.011 Moncayo, 2009, Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy, Mem Inst Oswaldo Cruz, 104, 17, 10.1590/S0074-02762009000900005 Marin-Neto, 2007, Pathogenesis of chronic Chagas heart disease, Circulation, 115, 1109, 10.1161/CIRCULATIONAHA.106.624296 Urbina, 2009, Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches, Acta Trop Viotti, 2006, Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial, Ann Intern Med, 144, 724, 10.7326/0003-4819-144-10-200605160-00006 Minoprio, 2001, Parasite polyclonal activators: new targets for vaccination approaches?, Int J Parasitol, 31, 588, 10.1016/S0020-7519(01)00171-0 Olivieri, 2002, Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection, Antimicrob Agents Chemother, 46, 3790, 10.1128/AAC.46.12.3790-3796.2002 Andrade, 1991, Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy, Mem Inst Oswaldo Cruz, 86, 187, 10.1590/S0074-02761991000200008 Segura, 1994, Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment, Mem Inst Oswaldo Cruz, 89, 213, 10.1590/S0074-02761994000200017 Andrade, 1989, Sequential changes of the connective matrix components of the myocardium (fibronectin and laminin) and evolution of cardiac fibrosis in mice infected with Trypanosoma cruzi, Am J Trop Med Hyg, 40, 252, 10.4269/ajtmh.1989.40.252 Souza, 2000, Enzymatic markers of heart lesion in mice infected with Trypanosoma cruzi and submitted to benznidazole chemotherapy, Parasitol Res, 86, 800, 10.1007/s004360000262 Ferraz, 2007, The anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas’ disease is less dependent on gamma interferon than that of benznidazole, Antimicrob Agents Chemother, 51, 1359, 10.1128/AAC.01170-06 Bustamante, 2008, Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease, Nat Med, 14, 542, 10.1038/nm1744 Ferraz, 2009, Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection, Antimicrob Agents Chemother, 53, 174, 10.1128/AAC.00779-08 Tarleton, 2007, The challenges of Chagas disease—grim outlook or glimmer of hope, PLoS Med, 4, e332, 10.1371/journal.pmed.0040332